期刊文献+

经皮冠状动脉介入治疗术后冠心病患者低密度脂蛋白胆固醇不同亚型水平与预后的关系 被引量:7

下载PDF
导出
摘要 目的 探讨经皮冠状动脉介入治疗术后LDL-C不同亚型水平与预后的关系。方法 选取2018年2月至2020年4月常州市中医医院收治的行经皮冠状动脉介入治疗的冠心病患者95例,所有患者术后随访1年。统计所有患者的预后情况,分析影响经皮冠状动脉介入治疗术后冠心病患者发生终点事件的因素。结果 95例患者中有20例(21.1%)出现终点事件。终点事件发生者的术前Gensini积分、空腹血糖(Fasting plasma glucose, FPG)、TG、TC、LDL-C3、LDL-C4、LDL-C5、LDL-C6和小的低密度脂蛋白胆固醇(small low-density lipoprotein cholesterol, sLDL-C)水平均高于终点事件未发生者,差异均有统计学意义(P<0.05)。多因素logistic回归分析显示,sLDL-C和FPG是影响经皮冠状动脉介入治疗术后冠心病患者发生终点事件的独立因素(P<0.05)。结论 冠心病患者经皮冠状动脉介入治疗术后心血管不良事件发生风险较高,术后sLDL-C水平与预后有关。
出处 《北京医学》 CAS 2022年第2期179-182,共4页 Beijing Medical Journal
  • 相关文献

参考文献4

二级参考文献28

  • 1韩雅玲,王守力,李毅,荆全民,马颖艳,王祖禄,王冬梅,栾波,王效增.急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J].中国介入心脏病学杂志,2005,13(1):9-12. 被引量:53
  • 2Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555. 被引量:1
  • 3Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651. 被引量:1
  • 4Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210. 被引量:1
  • 5Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13. 被引量:1
  • 6Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972. 被引量:1
  • 7Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932. 被引量:1
  • 8Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx. 被引量:1
  • 9Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243. 被引量:1
  • 10Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Cell Cardiol,2007,50 : 1742-1751. 被引量:1

共引文献2507

同被引文献93

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部